AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27788696 — intervention group
Group type: EXPERIMENTAL
Intervention: Mealtime intervention
Number of subjects: 100
Study 27788696 — intervention group
Group type: COMPARATOR
Intervention: Control group (received a guidebook on nutrition and culinary skills)
Number of subjects: 100
Study 24783431 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil-lymphocyte ratio (NLR) in patients with severe PE
Number of subjects: 3
Study 24783431 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean platelet volume (MPV)
Number of subjects: 3
Study 24783431 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-lymphocyte ratio (PLR)
Number of subjects: 3
Study 24783431 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte number for severe PE
Number of subjects: 3
Study 24783431 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil number for severe PE
Number of subjects: 3
Study 23863051 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT screening
Number of subjects: 53158
Study 23863051 — intervention group
Group type: COMPARATOR
Intervention: Chest radiography
Number of subjects: 53158
Study 21322822 — intervention group
Group type: EXPERIMENTAL
Intervention: cerebrolysin
Number of subjects: 76
Study 21322822 — intervention group
Group type: EXPERIMENTAL
Intervention: piracetam
Number of subjects: 76
Study 21322822 — intervention group
Group type: EXPERIMENTAL
Intervention: magne-B6
Number of subjects: 76
Study 18587639 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 44
Study 18587639 — intervention group
Group type: COMPARATOR
Intervention: Health education (HE; attention control)
Number of subjects: 44
Study 16652417 — intervention group
Group type: EXPERIMENTAL
Intervention: CH-1504
Number of subjects: 20
Study 16652417 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 20
Study 12784165 — intervention group
Group type: EXPERIMENTAL
Intervention: Running trial at 70% lactate threshold (LT)
Number of subjects: 18
Study 12784165 — intervention group
Group type: EXPERIMENTAL
Intervention: Running trial at LT intensity
Number of subjects: 18
Study 12784165 — intervention group
Group type: EXPERIMENTAL
Intervention: LT intensity exercise
Number of subjects: 18
Study 10554500 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cuff pressure group (< 15 mmHg)
Number of subjects: 190
Study 10554500 — intervention group
Group type: COMPARATOR
Intervention: High cuff pressure group (15‐25 mmHg)
Number of subjects: 190
Study 8681491 — intervention group
Group type: EXPERIMENTAL
Intervention: F105 (100 mg/m2)
Number of subjects: 0
Study 8681491 — intervention group
Group type: EXPERIMENTAL
Intervention: F105 (500 mg/m2)
Number of subjects: 0
Study 8681491 — intervention group
Group type: EXPERIMENTAL
Intervention: F105 (both doses)
Number of subjects: 0
Study 8681491 — intervention group
Group type: EXPERIMENTAL
Intervention: F105 (bolus dose every 21 days)
Number of subjects: 0
Study 1945642 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 58
Study 1945642 — intervention group
Group type: COMPARATOR
Intervention: Oxyhood
Number of subjects: 58
Study 1945642 — intervention group
Group type: EXPERIMENTAL
Intervention: NCPAP (after failure of oxyhood)
Number of subjects: 58
Study 6422096 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality therapy of nonspecific and host mediate immunotherapy and chemotherapy as an adjuvant to surgery
Number of subjects: 0
Study 6422096 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality therapy
Number of subjects: 0
Study 31435980 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttreatment functional status assessment (diet, public eating, speech)
Number of subjects: 495
Study 28387889 — intervention group
Group type: COMPARATOR
Intervention: Propofol (Group B)
Number of subjects: 63
Study 28387889 — intervention group
Group type: COMPARATOR
Intervention: Ketamine (Group C)
Number of subjects: 63
Study 28387889 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment (Group A)
Number of subjects: 63
Study 25926152 — intervention group
Group type: EXPERIMENTAL
Intervention: Dural splitting decompression (DSD)
Number of subjects: 160
Study 25926152 — intervention group
Group type: COMPARATOR
Intervention: Posterior fossa decompression with duraplasty (PFDD)
Number of subjects: 160
Study 24102165 — intervention group
Group type: EXPERIMENTAL
Intervention: GaAs laser therapy (peak power 10 W; pulse frequency 3000 Hz; average power 0.012 W; wavelength 980 nm; irradiation duration 300 sec; dose 12.73 J/cm²)
Number of subjects: 60
Study 24102165 — intervention group
Group type: COMPARATOR
Intervention: Sham laser treatment (control group)
Number of subjects: 60
Study 21376050 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking 3 or more cups/day of coffee
Number of subjects: 885
Study 19156018 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention delivered by Speech and Language Pathologists/Therapists targeting dysarthric speech
Number of subjects: 0
Study 19156018 — intervention group
Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 0
Study 17032921 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage therapy after relapse
Number of subjects: 609
Study 17032921 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age (under 20 years)
Number of subjects: 609
Study 17032921 — intervention group
Group type: EXPERIMENTAL
Intervention: Short duration of first remission (CR1)
Number of subjects: 609
Study 17032921 — intervention group
Group type: EXPERIMENTAL
Intervention: HSCT after relapse (in a selected subgroup)
Number of subjects: 609
Study 15326083 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 to 8 mg per day)
Number of subjects: 30
Study 15326083 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 to 100 mg per day)
Number of subjects: 30
Study 12002730 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 360 mg
Number of subjects: 15
Study 12002730 — intervention group
Group type: COMPARATOR
Intervention: Promethazine 30 mg
Number of subjects: 15
Study 12002730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9619533 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (s.c.) administration of gonadotrophins
Number of subjects: 71
Study 9619533 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (i.m.) administration of gonadotrophins
Number of subjects: 71
Study 9619533 — intervention group
Group type: EXPERIMENTAL
Intervention: Both s.c. and i.m. administration of gonadotrophins
Number of subjects: 71
Study 7613555 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (300 mg b.i.d.)
Number of subjects: 8
Study 7613555 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxofylline (400 mg t.i.d.)
Number of subjects: 8
Study 7613555 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 8
Study 7613555 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline and Doxofylline
Number of subjects: 8
Study 2198208 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg after the evening meal (R-P group)
Number of subjects: 87
Study 2198208 — intervention group
Group type: COMPARATOR
Intervention: Placebo before bedtime (P-R group)
Number of subjects: 87
Study 734639 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 5
Study 6282482 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE (Doxorubicin 45 mg/m2 i.v. day 1, Cyclophosphamide 1.0 mg/m2 i.v. day 1, VP16-213 50 mg/m2/day i.v. days 1-5)
Number of subjects: 174
Study 6282482 — intervention group
Group type: COMPARATOR
Intervention: ACE (Doxorubicin, Cyclophosphamide, VP16-213)
Number of subjects: 174
Study 31204273 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal suit T‐Balance
Number of subjects: 30
Study 31204273 — intervention group
Group type: COMPARATOR
Intervention: Forced air warming (FAW)
Number of subjects: 30
Study 29452814 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake removal of LMA
Number of subjects: 290
Study 29452814 — intervention group
Group type: COMPARATOR
Intervention: Deep removal of LMA
Number of subjects: 290
Study 26718305 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TA)
Number of subjects: 132
Study 26718305 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 132
Study 21824187 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice guidelines nutritional care (n = 85)
Number of subjects: 170
Study 21824187 — intervention group
Group type: COMPARATOR
Intervention: Usual nutritional care (n = 85)
Number of subjects: 170
Study 21142856 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance erlotinib
Number of subjects: 0
Study 21142856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17662432 — intervention group
Group type: EXPERIMENTAL
Intervention: Artiflex pIOL
Number of subjects: 20
Study 15327930 — intervention group
Group type: EXPERIMENTAL
Intervention: Autobiographical memory test with varying levels of retrieval support
Number of subjects: 1
Study 15327930 — intervention group
Group type: COMPARATOR
Intervention: Visual imagery tests
Number of subjects: 1
Study 11782042 — intervention group
Group type: EXPERIMENTAL
Intervention: Random-effects model
Number of subjects: 0
Study 11782042 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal models (GEE, WGEE, ML)
Number of subjects: 0
Study 9059684 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg terbinafine daily for 3 months
Number of subjects: 148
Study 9059684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 9059684 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg terbinafine daily for 3 or 6 months
Number of subjects: 148
Study 9059684 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine
Number of subjects: 148
Study 8112373 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil 0.05 microgram.kg‐1.min‐1
Number of subjects: 21
Study 8112373 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil 0.10 microgram.kg‐1.min‐1
Number of subjects: 21
Study 8112373 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil 0.20 microgram.kg‐1.min‐1
Number of subjects: 21
Study 8112373 — intervention group
Group type: COMPARATOR
Intervention: Nicorandil (all doses)
Number of subjects: 21
Study 8112373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 2873000 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbutaline
Number of subjects: 15
Study 2873000 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline
Number of subjects: 15
Study 2873000 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with theophylline and beta-adrenergic agonist
Number of subjects: 15
Study 28060048 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of inactivated hepatitis A vaccine (group 1)
Number of subjects: 3
Study 28060048 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of inactivated hepatitis A vaccine plus 1 dose of combined hepatitis A and B vaccine (group 2)
Number of subjects: 3
Study 28060048 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of combined hepatitis A and B vaccine (group 3)
Number of subjects: 3
Study 25454689 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of 12 mg I.V. ibandronate on day 1 then oral ibandronate 50 mg daily (arm A)
Number of subjects: 34
Study 25454689 — intervention group
Group type: COMPARATOR
Intervention: Standard oral therapy of 50 mg ibandronate daily from day 1 (arm B)
Number of subjects: 34
Study 25454689 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of 12 mg I.V. ibandronate (arm A)
Number of subjects: 34
Study 24973875 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil
Number of subjects: 180
Study 24973875 — intervention group
Group type: COMPARATOR
Intervention: propofol/alfentanil
Number of subjects: 180
Study 24973875 — intervention group
Group type: COMPARATOR
Intervention: midazolam/fentanyl
Number of subjects: 180
Study 23062542 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) with an implantable cardioverter‐defibrillator (ICD)
Number of subjects: 1699
Study 23062542 — intervention group
Group type: COMPARATOR
Intervention: ICD only
Number of subjects: 1699
Study 19583039 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% neem
Number of subjects: 40
Study 19583039 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% triclosan
Number of subjects: 40
Study 19583039 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gluconate
Number of subjects: 40
Study 19583039 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% sodium hypochlorite
Number of subjects: 40
Study 19583039 — intervention group
Group type: COMPARATOR
Intervention: distilled water (control)
Number of subjects: 40
Study 17223936 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation (SNS) at S3
Number of subjects: 8
Study 17223936 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation (SNS) at S2
Number of subjects: 8
Study 17223936 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous sacral nerve stimulation (SNS) over 3 weeks
Number of subjects: 8
Study 15774402 — intervention group
Group type: COMPARATOR
Intervention: Green land-based activities, training and social support; specific dosage and duration not mentioned.
Number of subjects: 0
Study 15774402 — intervention group
Group type: COMPARATOR
Intervention: Qualitative interviews and focus group discussions; specific dosage and duration not mentioned.
Number of subjects: 0
Study 11464350 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1,200 mg
Number of subjects: 22
Study 11464350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9670112 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (n = 21) - physical training including exercises on bicycle ergometer for 30 minutes (5 times a week), overall-conditioning exercises for 30 minutes daily, and 30 to 60 minutes of walking each day.
Number of subjects: 32
Study 9670112 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 11) - discharged home for 3 weeks with identical dietary instructions, no physical training.
Number of subjects: 32
Study 8152756 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Number of subjects: 148
Study 8152756 — intervention group
Group type: EXPERIMENTAL
Intervention: Powder-free surgical gloves with postoperative injections of 5-fluorouracil
Number of subjects: 148
Study 8152756 — intervention group
Group type: COMPARATOR
Intervention: Powdered surgical gloves
Number of subjects: 148
Study 3062134 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine alone (Aza)
Number of subjects: 0
Study 3062134 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine in combination with steroids
Number of subjects: 0
Study 3062134 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine treatment
Number of subjects: 0
Study 31962378 — intervention group
Group type: EXPERIMENTAL
Intervention: WBISI120
Number of subjects: 148
Study 31962378 — intervention group
Group type: EXPERIMENTAL
Intervention: WBISI
Number of subjects: 148
Study 31962378 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost comparison
Number of subjects: 148
Study 31774052 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal lavage with mupirocin
Number of subjects: 20
Study 31774052 — intervention group
Group type: COMPARATOR
Intervention: Nasal lavage without mupirocin
Number of subjects: 20
Study 28634690 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair (LHR) with large-pore polypropylene mesh
Number of subjects: 37
Study 28634690 — intervention group
Group type: COMPARATOR
Intervention: Open hernia repair (OHR) with retromuscular small-pore heavy-weight mesh
Number of subjects: 37
Study 25573141 — intervention group
Group type: EXPERIMENTAL
Intervention: Moldable positioner
Number of subjects: 62
Study 25573141 — intervention group
Group type: COMPARATOR
Intervention: Moldable positioner and cranial cup
Number of subjects: 62
Study 25573141 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial cup
Number of subjects: 62
Study 23562699 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual coil ICD leads
Number of subjects: 811
Study 23562699 — intervention group
Group type: COMPARATOR
Intervention: Single coil ICD leads
Number of subjects: 811
Study 21375428 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐polysiloxane soft cushion material
Number of subjects: 30
Study 21375428 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyether impression material
Number of subjects: 30
Study 21375428 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflexion
Number of subjects: 30
Study 19634962 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback condition
Number of subjects: 410
Study 19634962 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 410
Study 17473728 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%
Number of subjects: 26
Study 17473728 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 26
Study 15272659 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-thymol varnish (Cervitec), reapplied every 3 months
Number of subjects: 181
Study 15272659 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 181
Study 11579006 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care integrated with motivational interviewing, cognitive behavior therapy, and family intervention
Number of subjects: 0
Study 11579006 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 0
Study 9601172 — intervention group
Group type: EXPERIMENTAL
Intervention: All‐Bond 2 dental adhesive and Z100 composite resin
Number of subjects: 23
Study 9601172 — intervention group
Group type: EXPERIMENTAL
Intervention: A.R.T. Bond and Brilliant Dentin composite
Number of subjects: 23
Study 9601172 — intervention group
Group type: EXPERIMENTAL
Intervention: Prisma Universal Bond 3 and Variglass VLC polyacid‐modified composite resin
Number of subjects: 23
Study 8129387 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/day CGS16949A
Number of subjects: 0
Study 8129387 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/day CGS16949A
Number of subjects: 0
Study 8129387 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/day CGS16949A
Number of subjects: 0
Study 2679685 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence techniques implemented on a computer
Number of subjects: 150
Study 2679685 — intervention group
Group type: COMPARATOR
Intervention: Clinicians
Number of subjects: 150
Study 31816338 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthiness label anchored to the left
Number of subjects: 0
Study 31816338 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calorie label presented on the right
Number of subjects: 0
Study 31816338 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleasant choice key on the right
Number of subjects: 0
Study 31816338 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie food presented on the left
Number of subjects: 0
Study 30453316 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment condition (Sketch and Speak intervention)
Number of subjects: 44
Study 30453316 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 44
Study 28120524 — intervention group
Group type: COMPARATOR
Intervention: Test intervention
Number of subjects: 0
Study 26079469 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate insertion of contraceptive implant
Number of subjects: 414
Study 26079469 — intervention group
Group type: COMPARATOR
Intervention: Delayed insertion of contraceptive implant
Number of subjects: 414
Study 23561463 — intervention group
Group type: EXPERIMENTAL
Intervention: Practical prescription information or services
Number of subjects: 3940
Study 23561463 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination prescription information or services
Number of subjects: 3940
Study 23561463 — intervention group
Group type: EXPERIMENTAL
Intervention: Practical prescription information or services (for subjects prescribed a drug that treats an underlying condition)
Number of subjects: 3940
Study 23561463 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3940
Study 21765809 — intervention group
Group type: EXPERIMENTAL
Intervention: LED fluorescence microscopy (LED-FM)
Number of subjects: 2355
Study 21765809 — intervention group
Group type: COMPARATOR
Intervention: ZN smear microscopy
Number of subjects: 2355
Study 21765809 — intervention group
Group type: EXPERIMENTAL
Intervention: Three LED-FM smears
Number of subjects: 2355
Study 21765809 — intervention group
Group type: COMPARATOR
Intervention: Three ZN smears
Number of subjects: 2355
Study 19138461 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-question screen
Number of subjects: 204
Study 19138461 — intervention group
Group type: COMPARATOR
Intervention: CIS-R (Revised Clinical Interview Schedule)
Number of subjects: 204
Study 16700681 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming blanket
Number of subjects: 62
Study 16700681 — intervention group
Group type: COMPARATOR
Intervention: Usual care warmed cotton blankets
Number of subjects: 62
Study 15500134 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS blockers
Number of subjects: 0
Study 15500134 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 11579011 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 5 mg t.i.d. for 4 weeks
Number of subjects: 14
Study 11579011 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 14
Study 9649259 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg testosterone via intramuscular injection once a week for 15 weeks
Number of subjects: 31
Study 9649259 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg testosterone via intramuscular injection once a week for 15 weeks
Number of subjects: 31
Study 9649259 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg testosterone via intramuscular injection once a week for 15 weeks
Number of subjects: 31
Study 9649259 — intervention group
Group type: EXPERIMENTAL
Intervention: Total semen PSA levels decreased following administration of testosterone
Number of subjects: 31
Study 1863126 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural support with specific hip support during intensive care
Number of subjects: 45